Get the Daily Brief
Latest Biotech News
Sanofi stops Phase 3 CIDP trial after interim analysis flags insufficient efficacy
Sanofi halted its Phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy after an independent monitoring board concluded the trial was unlikely to achieve...
Record biotech IPO puts Parabilis on Nasdaq with $670M war chest
Parabilis Medicines priced an upsized IPO at $20 per share, raising $670 million and positioning the company for what would be the largest Nasdaq debut by a pure-play biopharma. The...
New cancer liquid biopsy pathway gets Medicare coverage for RNA-based screening
Geneoscopy said the US Centers for Medicare and Medicaid Services expanded coverage for its ColoSense stool-based RNA test within the national coverage determination for colorectal cancer...
10x Genomics buys into higher-plex proteomics with Proteintech Genomics
10x Genomics agreed to acquire Proteintech Genomics to broaden its proteomics capabilities and support integrated multiomics workflows. The deal is intended to merge 10x’s single-cell and spatial...
SonoThera raises $125M to push ultrasound-facilitated gene therapy into the clinic
SonoThera raised $125 million in a Series B to take its ultrasound-based gene therapy approach into clinical testing. The company’s non-viral platform uses microbubbles activated by ultrasound to...
Immunotherapy tool launch targets checkpoint combinations in vivo
Bio X Cell launched a ready-to-use, anti-mouse trispecific antibody in a PD-L1 × TIGIT × LAG3 format to enable combinatorial checkpoint studies in standard preclinical models. The company said the...
CNS drug target deal uses multimodal patient data for discovery
Verge Labs partnered with Tenacia Biotechnology under a CNS drug target identification agreement that uses foundation-model approaches and multimodal patient data. The data set cited in the report...
Personalis wins CE-IVD marking for blood collection kits
Personalis received CE-IVD marking for its EDTA and cfDNA blood collection kits in the European Union, enabling marketing and sale under the EU In Vitro Diagnostic Regulation. The kits are...
Allied precision diagnostics: Aignostics joins Pancreatic Cancer Action Network on spatial profiling
Aignostics and the Pancreatic Cancer Action Network (PanCAN) entered an alliance to apply Aignostics’ Atlas H&E tumor microenvironment software to spatially profile pancreatic cancer pathology...
GSK’s $10.6B push into near-approval lung cancer assets
GlaxoSmithKline agreed to acquire Nuvalent for $10.6 billion in cash, aiming to strengthen its lung cancer pipeline with two programs currently under FDA review. The deal adds ROS1 inhibitor...
Parabilis sets record with $670M biotech IPO and raises growth capital
Parabilis Medicines priced an upsized $670 million IPO, securing what is described as the largest biotech IPO on record for a newly public company. The oncology-focused developer is also raising...
Sanofi ends CIDP Phase 3 trial for futility
Sanofi stopped its Phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent monitoring board determined the trial was unlikely to...
Merck and Gilead advance weekly oral HIV therapy from two Phase 3 trials
Merck and Gilead reported positive results from two Phase 3 trials supporting a combination regimen designed to become the first weekly oral HIV pill. The approach pairs Merck’s islatravir with...
CNS drug-target deal: Verge Labs teams with Tenacia using multimodal patient data
Verge Labs partnered with Tenacia Biotechnology to identify new CNS drug targets using Verge’s foundation models and multimodal patient datasets. The collaboration leverages more than 12,000 brain...
SonoThera lands $125M Series B for ultrasound-based gene therapy
SonoThera raised $125 million in a Series B to advance an ultrasound-based non-viral gene delivery platform toward clinical development. The funding includes participation from venture firms and...
Adenovirus oncology platform expands after Firefly Bio acquisition by J&J
Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash, acquiring a degrader antibody conjugate platform. The acquisition is intended to expand J&J’s therapeutic toolkit around...
Europe’s drug pricing pressure reshapes pharma investment plans
Pfizer CEO Albert Bourla said the company is reassessing its planned investments in Germany amid policy proposals aimed at reducing drug spending. Reuters reported Bourla raised concerns in a...
Biotech discovery and instrumentation deal: CRISPR ‘destroyer’ enzyme concept emerges in Nature
Researchers engineered a CRISPR-based cancer approach designed to selectively destroy targeted cells using a specialized “destroyer” enzyme concept rather than classic gene-editing. The work,...
Beren Therapeutics adds $300M for rare disease drug as FDA decision nears
Beren Therapeutics raised $300 million through new financings as it prepares for an FDA decision later this fall for its rare disease drug candidate. The capital raise is explicitly positioned to...
Sanofi pipeline setback in CIDP
Sanofi halted its Phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) after an independent monitoring board concluded the antibody was unlikely to...